Disclosures Writing Group Disclosures
| Writing Group Member | Employment | Research Grant | Other Research Support | Speakers’ Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
|---|---|---|---|---|---|---|---|---|
| Philip B. Gorelick | University of Illinois | None | None | None | None | None | None | None |
| Angelo Scuteri | INRCA–IRCCS (Rome, Italy) |
None | None | None | None | None | None | None |
| Donna K. Arnett | University of Alabama at Birmingham |
None | None | None | None | None | None | None |
| David A. Bennett | Rush University Medical Center |
None | None | None | None | None | None | None |
| Sandra E. Black | University of Toronto |
NIH† | None | Eisai*; Janssen-Ortho*; Lundbeck*; Novartis Pharmaceuticals*; Pfizer* | None | None | Bristol-Myers Squibb*; Elan Pharmaceuticals*; GlaxoSmithKline*; Janssen-Ortho*; Lundbeck*; Novartis Pharmaceuticals*; Pfizer Wyeth Pharmaceuticals* |
None |
| Helena C. Chui | University of Southern California |
None | None | None | None | None | None | None |
| Charles DeCarl | University of California, Davis |
Merck†; NIH† | None | None | None | None | Bristol-Myers Squibb*; Merck*; Theravance* |
None |
| Steven M. Greenberg | Massachusetts General Hospital |
NIH†; NINDS† | None | None | None | None | Bristol-Myers Squibb*; Hoffmann-La Roche*; Janssen Alzheimer Immunotherapy*; Medtronic* |
None |
| Randall T. Higashida | University of California at San Francisco |
None | None | None | None | None | None | None |
| Costantino Iadecola | Weill Cornell Medical College |
NIH/NINDS† | None | None | None | None | None | None |
| Lenore J. Launer | National Institutes of
Health– National Institute on Aging |
NIH† | None | None | None | None | None | None |
| Stephane Laurent | University of Paris Descartes |
Daiichi-Sankyo*; Novartis*; Servier* |
None | AstraZeneca*; Boehringer Ingelheim*; Chiesi*; Daiichi-Sankyo*; Negma*; Novartis*; Pfizer*; Recordati*; Servier* |
None | None | None | None |
| Ruth Lindquist | University of Minnesota and Minneapolis Heart Institute |
None | None | None | None | None | None | None |
| Oscar L. Lopez | University of Pittsburgh |
NIA† | None | None | None | None | Bristol-Myers Squibb*; Pfizer* |
None |
| Peter M. Nilsson | Lund University of Sweden |
None | None | None | None | None | None | None |
| David Nyenhuis | University of Illinois |
NIH/NINDS† | None | None | None | None | None | None |
| Ronald C. Petersen | Mayo Clinic | None | None | None | None | None | Elan Pharma*; GE Healthcare*; Wyeth Pharmaceuticals* |
None |
| Gustavo C. Roman | Methodist Neurological Institute in Houston, TX |
None | None | Ferrer* | None | None | Ferrer* | None |
| Julie A. Schneider | Rush Alzheimer's Disease Center– Rush University |
NIH† | None | None | None | None | Avid Radiopharmaceuticals*; GE Healthcare* |
None |
| Frank W. Sellke | Lifespan, Brown Medical School |
Capstone*; Ikaria*; NIH† |
None | None | Pfizer† | None | Cubist DSMB*; Edwards Lifesciences DSMB*; Novo Nordisk DSMB* |
None |
| Sudha Seshadri | Boston University School of Medicine |
NIA† | None | None | None | None | None | None |
| Christophe Tzourio | INSERM–Paris,France (National Institute for Health and Medical Research) |
French Alzheimer Plan† | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (1) the person receives $10 000 or more during any 12-month period, or 5% or more of the person's gross income; or (2) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.